Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T18:55:39.840Z.
Calculation as of: 2026-10-06T18:55:39.840Z.
Quote observation: 2026-10-06T18:55:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$732.76M
PB Ratio
N/A
TTM Avg
11.71
3Y Avg
10.59
5Y Avg
22.59
Market Cap
$777.61M
PB Ratio
4.46
TTM Avg
4.64
3Y Avg
3.11
5Y Avg
3.40
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $754.65M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $750.73M | 3.72 | 3.19 | 1.68 | 1.76 |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.02M | 4.02 | 2.88 | 2.93 | 2.84 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $735.63M | 5.83 | 4.72 | 7.10 | 4.64 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $732.76M | N/A | 11.71 | 10.59 | 22.59 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.61M | 4.46 | 4.64 | 3.11 | 3.40 |
| Varex Imaging Corporation (VREX)vs › | $778.22M | 1.57 | 1.12 | 1.11 | 1.42 |
| Sana Biotechnology, Inc. (SANA)vs › | $784.17M | 5.07 | 6.57 | 4.53 | 3.60 |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | 0.57 | 0.85 | 0.83 | 0.96 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
